AgingResearch.NewsJoin free

Sana Biotechnology

CompanyUnited States

Sana Biotechnology develops one asset, in phase 1 (SC262 in large B-cell lymphoma). Mostly cell therapy acting on CD22; based in the United States.

1
Asset
Furthest stage
Phase 1
Raised
US$844m
1
Trial
1
Signal

Pipeline

1

  • SC262

    Allogeneic hypoimmune CAR T cells target CD22-expressing malignant B cells.

    Phase 1, Cell therapy, CD22, large B-cell lymphoma, non-Hodgkin lymphoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Funding rounds and grants3
  • Signals2
  • Similar companies6

Intelligence